Urobilinogen is converted from conjugated bilirubin. Conjugated bilirubin is unconjugated in the lower part of the small intestine and the colon by the action of intestinal bacteria, and the bilirubin undergoes several stages of reduction to become urobilinogen, which is then excreted in the feces. Indicators of urobilinogen are mostly associated with liver disease. Hepatocellular jaundice is a common clinical form of jaundice, which is mainly caused by damage to the liver cells. When hepatocytes are diseased, liver function is affected and the liver is not able to take in properly, resulting in the formation of indirect bilirubin accumulation in the blood; at the same time, direct bilirubin in the blood stream also increases due to obstruction of bile excretion. As both indirect and direct bilirubin increase in the blood, both bilirubin and urobilinogen increase in the urine. This leads to the formation of hepatocellular jaundice. If the jaundice is caused by hepatocyte degeneration and necrosis, liver protection treatment should be actively carried out, generally only one or two liver-protective drugs should be used, and too many liver-protective drugs should not be used, otherwise it will also increase the physiological burden of the liver; if it is caused by toxic hepatitis, it can be treated with reduced glutathione to accelerate the detoxification function of liver cells. Magnesium isoglycyrrhizate, ornithine menthylate and other drugs are commonly used to reduce jaundice. Certain Chinese medicines such as gardenia yellow, bitter ginseng or bitter yellow have anti-inflammatory, cholagogic and anti-yellowing effects and can be used as appropriate.